Central serous retinopathy (often called central serous chorioretinopathy, or CSC) is a condition where fluid collects beneath the retina at the back of the eye, causing a small blister-like detachment that distorts central vision. It most commonly affects men between the ages of 20 and 50, and roughly 85% of cases resolve on their own within three to four months. The remaining 15% develop a chronic form that can lead to lasting vision changes if left untreated.
How Fluid Builds Up Under the Retina
The retina sits on top of a thin layer of cells called the retinal pigment epithelium (RPE), which acts as a barrier between the retina and the blood vessel layer beneath it (the choroid). In CSC, the blood vessels in the choroid become abnormally enlarged and leak fluid. This creates pressure that compresses the smaller blood vessels above them, damaging the RPE barrier. Once the barrier is overwhelmed, fluid seeps through into the space beneath the retina, lifting it slightly off its normal position.
Think of it like water pressure forcing its way through a weakened seal. The RPE can develop tiny rips or areas of dysfunction, and as long as the pressure remains elevated or the barrier stays compromised, fluid continues to accumulate. This pocket of fluid, centered on the macula (the part of the retina responsible for sharp central vision), is what causes the characteristic visual symptoms.
What CSC Feels Like
The symptoms of CSC are subtle enough that some people initially dismiss them. The most common complaint is mild blurring in the center of your visual field, often in just one eye. Colors may look slightly washed out or dimmer in the affected eye compared to the other.
Many people notice metamorphopsia, where straight lines appear wavy or bent. If you look at a door frame or the edge of a book, it may seem to bow or ripple. Some people also experience micropsia, where objects appear smaller than they actually are, or notice a dark or gray spot in their central vision (a central scotoma). Another subtle sign is a shift toward farsightedness in the affected eye, caused by the fluid pushing the retina slightly forward and changing its focal point.
Stress, Steroids, and Other Risk Factors
The two biggest risk factors for CSC are psychological stress and corticosteroid use. One case-control study found that corticosteroid use increased the risk of developing CSC by a factor of 37.5, making it the strongest known trigger. This applies to steroids taken by mouth, inhaled for asthma, injected into joints, or applied as skin creams. If you develop CSC while using any form of corticosteroid, stopping the medication (with your prescriber’s guidance) is often the first step in treatment.
The stress connection runs deeper than just feeling anxious. CSC has long been linked to “Type A” personalities, though newer research suggests this association may be oversimplified. A study in the European Journal of Ophthalmology found that CSC patients scored higher on measures of neuroticism, anxiety, and aggression-hostility compared to other groups. These personality traits are associated with elevated cortisol levels, particularly in men, which may explain why stress acts as a biological trigger rather than just a vague contributing factor. The body’s own cortisol, produced during prolonged stress, appears to act on the choroidal blood vessels in much the same way that external steroid medications do.
Male sex is itself a significant risk factor, with men affected roughly three to six times more often than women.
How CSC Is Diagnosed
An eye doctor can often suspect CSC during a routine dilated exam, but confirming the diagnosis requires imaging. Optical coherence tomography (OCT) is the primary tool. It produces a cross-sectional scan of the retina and can clearly show the pocket of subretinal fluid, measure its thickness, and reveal changes in the RPE such as small detachments or irregularities. OCT also measures choroidal thickness, which is typically increased in CSC eyes.
Fluorescein angiography, where a dye is injected into a vein and photographed as it passes through the eye’s blood vessels, can pinpoint the exact location of the leak. The dye appears in one of two patterns: an “ink blot” pattern, where it spreads outward from a single point, or the less common “smokestack” pattern, where it rises vertically before fanning out. The smokestack pattern shows up in only 7% to 29% of cases but is considered nearly diagnostic of CSC when present. Indocyanine green angiography, which uses a different dye that highlights the choroidal vessels more effectively, can provide additional detail when the diagnosis is uncertain.
Acute vs. Chronic CSC
CSC is generally classified as acute when the fluid resolves within four to six months, and chronic when it persists beyond that window. Most first episodes are acute and self-limiting, with the fluid reabsorbing and vision returning to normal or near-normal without any intervention. However, about 15% of patients develop chronic CSC, where the fluid either never fully clears or keeps returning.
Chronic CSC carries a higher risk of permanent damage. Prolonged fluid exposure can harm the photoreceptor cells in the retina, leading to lasting reductions in visual sharpness, persistent color vision changes, or ongoing distortion. This is why the transition from “wait and watch” to active treatment matters.
Recurrence Rates
Even when CSC resolves completely, it has a strong tendency to come back. A large multicentre study of 538 eyes found that 47% experienced at least one recurrence, with an average of about 1.4 episodes per affected eye over the follow-up period. Recurrences can happen months or years after the first episode and may affect the same eye or the opposite one. Continued corticosteroid use and unmanaged stress are among the factors that increase the likelihood of recurrence.
Treatment Approaches
For a first episode of acute CSC, the standard approach is observation. Most doctors will monitor the eye with periodic OCT scans for three to six months, giving the fluid a chance to resolve on its own. During this time, reducing stress and discontinuing any corticosteroid medications (when medically possible) can help speed recovery.
When fluid persists beyond four to six months, or when vision is significantly affected, active treatment is considered. Photodynamic therapy (PDT) is one of the most studied options. It involves injecting a light-sensitive medication into a vein and then activating it with a low-energy laser directed at the area of leakage. This helps seal the abnormal choroidal vessels without damaging the overlying retina. Reduced-dose or reduced-energy versions of PDT are commonly used to minimize side effects.
Oral medications that block mineralocorticoid receptors have emerged as another option for chronic CSC. These drugs counteract the effect of cortisol on the choroidal vessels. Studies have found them effective and well-tolerated for chronic cases, with patients showing resolution of subretinal fluid and improvement in visual acuity. In some cases, improvements persisted for months after stopping the medication.
Thermal laser treatment, where a focused laser is applied directly to the leaking spot, is an older approach still used selectively when the leak is located away from the center of the macula. It creates a small scar that seals the leak but can itself cause a permanent blind spot, so it is avoided when the leak sits too close to the area of sharpest vision.
What to Expect Long Term
Most people with a single acute episode recover good vision, though some notice subtle lingering differences between their two eyes, particularly in contrast sensitivity or color perception, even after the fluid is completely gone. These differences are caused by mild photoreceptor changes that occurred while the retina was detached and may or may not improve fully over time.
For those with chronic or frequently recurring CSC, the visual outlook depends heavily on how long the fluid persists and how quickly treatment is initiated. Prolonged or repeated episodes can lead to thinning of the retinal layers and progressive vision loss. Because recurrence affects nearly half of all patients, staying aware of subtle visual changes and having prompt follow-up imaging when symptoms return gives you the best chance of preserving long-term vision.